Protalix BioTherapeutics, Inc. (PLX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 25M 50M 75M FY21: 38.4M FY22: 47.6M FY23: 65.5M FY24: 53.4M FY25: 52.7M FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 1.5M 3M 4.5M FY13: 0 FY14: 2.9M FY15: 3.6M FY16: 801K FY17: 4M FY13 FY14 FY15 FY16 FY17

Operating Income Annual

-21M -14M -7M 0 7M 14M 21M FY21: -20.5M FY22: -13M FY23: 10.5M FY24: 3.9M FY25: -5.5M FY21 FY22 FY23 FY24 FY25

Net Income Annual

-30M -20M -10M 0 10M 20M 30M FY21: -27.6M FY22: -14.9M FY23: 8.3M FY24: 2.9M FY25: -6.6M FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 10M 20M 30M FY21: 16.3M FY22: 19.6M FY23: 23M FY24: 24.3M FY25: 27M FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-27M -18M -9M 0 9M 18M 27M FY21: -10.3M FY22: -25M FY23: -1.3M FY24: 8.7M FY25: -12M FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-27M -18M -9M 0 9M 18M 27M FY21: -11.7M FY22: -25.6M FY23: -2.5M FY24: 7.4M FY25: -13.6M FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 30M 60M 90M FY21: 44.1M FY22: 48.5M FY23: 82.4M FY24: 81.1M FY25: 78.5M FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.75 -0.50 -0.25 0.00 0.25 0.50 0.75 Q3 '21: -0.53 Q4 '21: -0.62 Q1 '22: -0.53 Q2 '22: -0.39 Q3 '22: -0.37 Q4 '22: -0.30 Q1 '23: -0.30 Q2 '23: 0.02 Q3 '23: 0.05 Q4 '23: 0.09 Q1 '24: 0.08 Q2 '24: -0.16 Q3 '24: -0.09 Q4 '24: 0.04 Q1 '25: 0.05 Q2 '25: 0.08 Q3 '25: 0.08 Q4 '25: -0.09 Q1 '26: 0.18 Q2 '26: 0.23 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.